Holen Sie sich die Stockscreener-App
6.44
8.38%
-0.60
Schlusskurs vom Vortag:
$7.04
Offen:
$6.62
24-Stunden-Volumen:
34.02M
Relative Volume:
10.11
Marktkapitalisierung:
$1.35B
Einnahmen:
$557.51M
Nettoeinkommen (Verlust:
$-35.71M
KGV:
-35.78
EPS:
-0.18
Netto-Cashflow:
$15.50M
1W Leistung:
-7.19%
1M Leistung:
-18.46%
6M Leistung:
-8.38%
1J Leistung:
-13.54%
1-Tages-Spanne:
$6.00
$6.98
1-Wochen-Bereich:
$6.00
$7.335
52-Wochen-Spanne:
$6.00
$11.31
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Firmenname
Biocryst Pharmaceuticals Inc
Sektor
Telefon
919-859-1302
Adresse
4505 EMPEROR BOULEVARD, DURHAM, NC
Vergleichen Sie BCRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
6.435 | 1.52B | 557.51M | -35.71M | 15.50M | -0.18 |
|
ZTS
Zoetis Inc
|
143.28 | 63.05B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.79 | 43.33B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.165 | 40.43B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.11 | 22.97B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
434.04 | 19.90B | 3.08B | 1.24B | 1.07B | 25.61 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-01 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-02-25 | Eingeleitet | Wedbush | Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-09-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-02-22 | Hochstufung | Needham | Hold → Buy |
| 2022-11-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-08-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-04-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-04-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-08-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-03-01 | Eingeleitet | Cowen | Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-05-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-15 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-08-08 | Fortgesetzt | JP Morgan | Overweight |
| 2018-07-17 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | Eingeleitet | Seaport Global Securities | Neutral |
| 2018-01-02 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | Eingeleitet | Barclays | Equal Weight |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-09-06 | Hochstufung | Jefferies | Hold → Buy |
| 2017-02-16 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-08-12 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Bestätigt | FBR Capital | Outperform |
| 2016-02-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2016-02-09 | Herabstufung | Needham | Buy → Hold |
Alle ansehen
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
Covington, Sidley Guide $700M BioCryst Allergic Disease Deal - Law360
BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate' - Benzinga
BioCryst Pharmaceuticals, Inc. agreed to acquire Astria Therapeutics, Inc.. - MarketScreener
BioCryst goes ‘all in’ on rare swelling disease with Astria deal - BioPharma Dive
Here’s Why Astria Therapeutics Stock (ATXS) Exploded Today - TipRanks
BioCryst to Acquire Astria Therapeutics in $700 Million Deal - Contract Pharma
BioCryst deepens rare diseases focus with $700 million deal for Astria - Reuters
BioCryst To Acquire Astria Therapeutics - citybiz
Mergers and acquisitions - TradingView
Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals Stock? - TradingView
ATXS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Astria Therapeutics, Inc. Is Fair to Shareholders - Business Wire
BioCryst to Acquire Astria Therapeutics for $700 Million Includi - GuruFocus
BioCryst Announces Acquisition of Astria Therapeutics (ATXS) at $13.00 Per Share - GuruFocus
BioCryst (BCRX) to Acquire Astria Therapeutics in $700M Deal - GuruFocus
BioCryst To Acquire Astria Therapeutics In $700M Deal - Stocktwits
BioCryst Pharmaceuticals To Acquire Astria Therapeutics In $700 Million Cash-and-Stock Deal - Nasdaq
BioCryst to acquire Astria Therapeutics for $700 million - Investing.com
BioCryst to acquire Astria Therapeutics for $700 million By Investing.com - Investing.com Canada
BioCryst to Acquire Astria in Deal Valued at $700 Million - MarketScreener
BioCryst to buy Astria Therapeutics in $700 million deal - Yahoo Finance
BioCryst To Acquire Astria Therapeutics In $700 Mln Cash-and-Stock Deal - Nasdaq
Astria Therapeutics stock soars after BioCryst acquisition announcement, BioCryst falls By Investing.com - Investing.com Canada
BioCryst Announces Merger with Astria Therapeutics - TipRanks
BioCryst to buy Astria Therapeutics for $13 per share - MSN
BioCryst Pharmaceuticals Appoints New Board Member - TradingView
BioCryst Pharmaceuticals to Acquire Astria Therapeutics, Expanding HAE Portfolio with Navenibart in $920 Million Deal - Quiver Quantitative
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile - GlobeNewswire
Is BioCryst Pharmaceuticals Inc. stock bottoming outEntry Point & Safe Capital Investment Plans - newser.com
BioCryst's Orladeyo up for FDA review in pediatric HAE patients - MSN
Has BioCryst Pharmaceuticals Inc. formed a bullish divergenceWeekly Profit Analysis & Trade Opportunity Analysis Reports - newser.com
Why retail investors pile into BioCryst Pharmaceuticals Inc. stockWeekly Stock Analysis & AI Based Buy/Sell Signal Reports - newser.com
Applying sector rotation models to BioCryst Pharmaceuticals Inc.Quarterly Investment Review & Long-Term Safe Return Strategies - newser.com
Will BioCryst Pharmaceuticals Inc. stock maintain growth storyEarnings Recap Summary & Consistent Profit Trading Strategies - newser.com
Quantitative breakdown of BioCryst Pharmaceuticals Inc. recent move2025 Dividend Review & Community Consensus Trade Signals - newser.com
What technical models suggest about BioCryst Pharmaceuticals Inc.’s comeback2025 Growth vs Value & Safe Entry Momentum Stock Tips - newser.com
BioCryst Bets Big On Rare Disease With ORLADEYO’s Growth - Finimize
How high can BioCryst Pharmaceuticals Inc. stock goAnalyst Downgrade & Fast Entry High Yield Stock Tips - newser.com
Multi factor analysis applied to BioCryst Pharmaceuticals Inc.Earnings Performance Report & AI Driven Stock Movement Reports - newser.com
How BioCryst Pharmaceuticals Inc. stock reacts to oil pricesAnalyst Upgrade & Proven Capital Preservation Tips - newser.com
Weiss Ratings Reiterates "Sell (D-)" Rating for BioCryst Pharmaceuticals (NASDAQ:BCRX) - MarketBeat
RBC Capital Sticks to Their Buy Rating for BioCryst (BCRX) - The Globe and Mail
Is BioCryst Pharmaceuticals Inc. stock poised for growthJuly 2025 Patterns & Stock Portfolio Risk Management - newser.com
BioCryst Pharma Nears Defining FDA Moment For Pediatric HAE Therapy - RTTNews
RBC Lifts Price Target on BioCryst Pharmaceuticals to $14 From $13, Keeps Outperform Rating - MarketScreener
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Rating Upgraded by Zacks Research - MarketBeat
BioCryst Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Volatility - Markets Mojo
Down 14.3% in 4 Weeks, Here's Why BioCryst (BCRX) Looks Ripe for a Turnaround - Yahoo Finance
Custom strategy builders for tracking BioCryst Pharmaceuticals Inc.Weekly Trade Summary & Technical Pattern Based Signals - newser.com
BioCryst Pharmaceuticals Inc. stock chart pattern explainedJuly 2025 Momentum & AI Powered Buy and Sell Recommendations - newser.com
Applying chart zones and confluence areas to BioCryst Pharmaceuticals Inc.July 2025 Short Interest & Technical Entry and Exit Tips - newser.com
BioCryst Pharmaceuticals (BCRX): Exploring Valuation After Recent Share Price Drift - Sahm
Finanzdaten der Biocryst Pharmaceuticals Inc-Aktie (BCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.95%
2.89%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):